Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Back

ESC Professional Premium Access

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Session: Oral anticoagulation in patients with atrial fibrillation

Topic: Anticoagulants

Speaker: Mr M. Grymonprez (Ghent, BE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Mr Maxim Grymonprez

Ghent University, Ghent (Belgium)

0 follower

7 more presentations in this session

Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study

Speaker: Doctor M. Abou Kaoud (Tel Aviv, IL)

Access

Abstract

Slides

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

Speaker: Doctor S. Deitelzweig (New Orleans, US)

Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

Speaker: Doctor S. Patel (Boston, US)

Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis

Speaker: Doctor T. Chao (Taipei, TW)

Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients

Speaker: Doctor J. Kim (Seoul, KR)

Access the full session

Oral anticoagulation in patients with atrial fibrillation

Speakers: Mr M. Grymonprez, Doctor M. Abou Kaoud, Doctor S. Deitelzweig, Doctor S. Patel, Doctor T. Chao...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

About the speaker

Mr Maxim Grymonprez

7 more presentations in this session

Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis

Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients

Access the full session

Oral anticoagulation in patients with atrial fibrillation

About the event

ESC Congress 2023

ESC 365 is supported by